# Phase II Neoadjuvant Chemotheraphy (Gemcitabine and Nab-Paclitaxel vs. mFOLFIRINOX) and Sterotatic Body Radiation Therapy for Borderline Resectable Pancreatic Cancer

> **NCT02241551** · PHASE2 · TERMINATED · sponsor: **Nathan Bahary, MD** · enrollment: 2 (actual)

## Conditions studied

- Borderline Resectable Pancreatic Cancer

## Interventions

- **DRUG:** gemcitabine/nab-paclitaxel
- **DRUG:** mFOLFIRINOX

## Key facts

- **NCT ID:** NCT02241551
- **Lead sponsor:** Nathan Bahary, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-12
- **Primary completion:** 2017-03-03
- **Final completion:** 2017-03-03
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Study was terminated with the IRB ended early as logistical concerns of the SBRT
- **Last updated:** 2018-07-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02241551

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02241551, "Phase II Neoadjuvant Chemotheraphy (Gemcitabine and Nab-Paclitaxel vs. mFOLFIRINOX) and Sterotatic Body Radiation Therapy for Borderline Resectable Pancreatic Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02241551. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*